
Infant Bacterial Therapeutics Investor Relations Material
Latest events

Study Update
Infant Bacterial Therapeutics

Q1 2025
7 May, 2025

Q4 2024
13 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Infant Bacterial Therapeutics
Access all reports
Infant Bacterial Therapeutics is a Sweden-based pharmaceutical company focused on developing microbiome-based treatments for diseases affecting premature infants and children. Its primary focus is on preventing necrotizing enterocolitis and other serious conditions using live bacterial therapies. Infant Bacterial Therapeutics is headquartered in Stockholm, Sweden, and its shares are listed on the NASDAQ Stockholm.
Latest articles
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
Ticker symbol
IBT
Country
🇸🇪 Sweden